Clinical Outcomes in Patients Admitted for ST-Elevation Myocardial Infarction with vs Without Systemic Lupus Erythematosus: An Analysis from National Inpatient Sample Database (2015-2018)

Hamza Liaqat¹, Muhammad Qureshi², Awais Farooq³, Mashal Awais², Amar Patel⁴ and Aisha Barlas⁵, ¹Wah Medical College, Wah Cantt, Pakistan, ²Southeast Health Internal Medicine Residency Prog., Dothan, AL, ³University of Illinois Chicago, Chicago, IL, ⁴Texas Tech University Health Sciences Center, El paso, TX, ⁵Mercy Health, Rockford, IL

Meeting: ACR Convergence 2023

Keywords: Heart disease, Mortality, Myocardial Infarction, risk assessment, Systemic lupus erythematosus (SLE)

Session Information

Date: Monday, November 13, 2023

Title: (1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Impact of systemic lupus erythematosus (SLE) on the clinical outcomes of patients admitted for ST-elevation myocardial infarction (STEMI).

Methods: Patient data was collected for years 2015-2018 from National Inpatient Sample using the International Classification Of Disease Revision Codes (ICD-10). We selected patients who were admitted with the diagnosis of STEMI. We then divided our patient population into two groups, those without SLE (STEMI group) and patients with an underlying diagnosis of SLE (STEMI/SLE group). Multivariate Logistic Regression and Mann-Whitney U testing were employed for this purpose.

Results: Our study included 1,009,407 patients with a primary diagnosis of STEMI. Of these patients, 4150 (0.41%) had an underlying diagnosis of SLE. The mean age of patients in the STEMI group was 67 years, compared to 61 years in the STEMI/SLE group. 61.8% were males in STEMI patients and female predominance was noted in STEMI/SLE group, 81.3%. The predominant race involved in both groups was noted to be Caucasian, 70.5% in the STEMI group vs 58.53% in STEMI/SLE group. In regards to mortality, we found that the underlying diagnosis of SLE in STEMI patients was associated with an increased risk of mortality, adjusted odds ratio of 1.278 (95% CI 1.09-1.48, p< 0.05). The length of stay in STEMI patients was 4.5 days, vs 4.7 days in the STEMI/SLE group. Hospitalization charges were noted to be $84522 and $82783 in STEMI and STEMI/SLE groups respectively.

Conclusion: This nationwide study showed that concomitant SLE in patients admitted with STEMI was associated with a statistically significant increase in inpatient mortality and length of stay. However, reduced cost of hospitalization was noted among STEMI/SLE patients.

Disclosures: H. Liaqat: None; M. Qureshi: None; A. Farooq: None; M. Awais: None; A. Patel: None; A. Barlas: None.

To cite this abstract in AMA style:

Liaqat H, Qureshi M, Farooq A, Awais M, Patel A, Barlas A. Clinical Outcomes in Patients Admitted for ST-Elevation Myocardial Infarction with vs Without Systemic Lupus Erythematosus: An Analysis from National Inpatient Sample Database (2015-2018) [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/clinical-outcomes-in-patients-admitted-for-st-elevation-myocardial-infarction-with-vs-without-systemic-lupus-erythematosus-an-analysis-from-national-inpatient-sample-database-2015-2018/. Accessed .

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-outcomes-in-patients-admitted-for-st-elevation-myocardial-infarction-with-vs-without-systemic-lupus-erythematosus-an-analysis-from-national-inpatient-sample-database-2015-2018/